Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li Sells 843 Shares

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 843 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $17.37, for a total value of $14,642.91. Following the completion of the transaction, the vice president now owns 13,345 shares of the company’s stock, valued at $231,802.65. This represents a 5.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Surrozen Trading Down 1.1 %

Shares of NASDAQ:SRZN opened at $12.81 on Thursday. Surrozen, Inc. has a 52 week low of $6.00 and a 52 week high of $18.17. The firm’s fifty day moving average is $11.11 and its 200-day moving average is $9.97.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($2.77) by $2.33. The company had revenue of $10.00 million for the quarter. As a group, equities analysts expect that Surrozen, Inc. will post -7.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Friday, January 3rd.

Hedge Funds Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently made changes to their positions in SRZN. Armistice Capital LLC bought a new position in Surrozen during the 2nd quarter worth approximately $2,080,000. Nantahala Capital Management LLC acquired a new stake in shares of Surrozen during the second quarter worth $2,050,000. Stonepine Capital Management LLC raised its stake in Surrozen by 66.5% during the third quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock worth $1,318,000 after buying an additional 43,916 shares during the last quarter. Finally, CVI Holdings LLC bought a new position in Surrozen during the second quarter worth $711,000. 66.57% of the stock is owned by institutional investors and hedge funds.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.